Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ≥60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): results of the safety run-in phase
低剂量阿扎胞苷、吡格列酮和全反式维甲酸治疗对接受标准诱导化疗无效的≥60岁急性髓系白血病患者是安全的(AMLSG 26-16/AML-ViVA):安全性导入期结果
期刊:Haematologica
影响因子:7.9
doi:10.3324/haematol.2023.283864
Heudobler, Daniel; Luke, Florian; Hahn, Joachim; Grube, Matthias; Schlosser, Pavla; Kremers, Stephan; Sudhoff, Thomas; Westermann, Jorg; Hutter-Kronke, Marie Luise; Schlenk, Richard F; Weber, Daniela; Paschka, Peter; Zeman, Florian; Dohner, Hartmut; Herr, Wolfgang; Reichle, Albrecht; Thomas, Simone